Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
M. Fassnacht, A. Berruti, E. Baudin, M.J. Demeure, J. Gilbert, H. Haak, M. Kroiss, D.I. Quinn, E. Hesseltine, C.L. Ronchi, M. Terzolo, T.K. Choueiri, S. Poondru, T. Fleege, R. Rorig, J. Chen, A.W. Stephens, F. Worden, G.D. Hammer*
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study'. Together they form a unique fingerprint.